Please login to the form below
Synagis
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.
Sobi shows strong growth despite haemophilia competition
November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating
US, EU regulators back rapid reviews of AZ’s RSV med
MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s
AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi
s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi
AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Keytruda doubles five-year survival rate in NSCLC
- FDA approves Roche’s Actemra COVID-19 trial
PMHub
claire@dovetailstrategies.com
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
